# Piper Sandler

> Piper Sandler is a VC fund backing Biotechnology and Health Care. See 35 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Minneapolis, United States
- Total investments: 35
- Last investment: Jul 2026
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/piper-jaffray
- X (Twitter): https://twitter.com/piperjaffrayco
- Website: https://pipersandler.com
- Facebook: https://www.facebook.com/pg/piperjaffraycompanies

Piper Sandler is a VC fund in Minneapolis focused on Biotechnology and Health Care. Piper Jaffray is a leading full-service investment bank and asset management firm serving clients in the U.S. and internationally.Piper Jaffray is focused on mergers and acquisitions, financial restructuring, public offerings, public finance, institutional brokerage, investment management, and securities research. Through its principalsubsidiary, Piper Jaffray & Co., the company targets corporations, institutional investors, and public entities.Founded in 1895, the firm is headquartered in Minneapolis and has offices across the United States and in London, Hong Kong1 and Zurich.

## Contacts

5 contacts available for Piper Sandler. Shizune tracks 10 team members at Piper Sandler. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/piper-jaffray?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 13 | 37% |
| Health Care | 12 | 34% |
| Medical Device | 6 | 17% |
| Manufacturing | 5 | 14% |
| Medical | 4 | 11% |

60 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 8 | 23% |
| Series B | 7 | 20% |
| Series C | 6 | 17% |
| Funding Round | 5 | 14% |
| Series E | 3 | 9% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 30 | 86% |
| Australia | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Chad Abraham | Chief Executive Officer | 0 | — |
| Timothy Carter | Managing Director, Chief Financial Officer | 0 | — |
| Tom Schnettler | Vice Chairman , Managing Director | 5 | — |
| Christine Esckilsen | Managing Director, Chief Human Capital Officer | 0 | — |
| David Crosby | Managing director | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AdvanCell | AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $315M | Series D | Jul 15, 2026 |  |
| First Mutual Holding | First Mutual Holding Co. (FMHC) is a member-owned holding company headquartered in Ohio. FMHC provides a structure that allows independent affiliate banks to continue to serve their communities and grow as member-owned institutions. Affiliates of FMHC include First Federal Lakewood (Lakewood, OH), First Mutual Bank FSB, (Belpre, OH), Blue GrassFederal Savings and Loan (Paris, KY), Warsaw Federal Savings and Loan (Cincinnati, OH) and Martinsville First Savings Bank (Martinsville, VA). | $25M | Debt Financing | Jun 23, 2026 |  |
| CereVasc | CereVasc is a medical device company that develops treatments for neurological diseases, with a primary focus on communicating hydrocephalus. The company is advancing the eShunt® System, an investigational device designed to manage cerebrospinal fluid through a minimally invasive endovascular approach rather than traditional open neurosurgery. Itstechnology includes an implantable cerebrospinal fluid shunt and associated delivery components intended to treat hydrocephalus while reducing the need for invasive surgical procedures. CereVasc conducts clinical studies to evaluate the safety and effectiveness of the eShunt System in patients with conditions such as normal pressure hydrocephalus and other forms of communicating hydrocephalus. The company’s work centers on developing device-based therapies that improve access to treatment for patients with neurological disorders. | $85M | Series C | Jun 04, 2026 |  |
| Kandu Health | Kandu Health is a tech-enabled healthcare company that provides stroke recovery training, stroke detection research, and education services. |  | Venture - Series Unknown | Jan 12, 2026 |  |
| Indivior | Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treatedchronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior. | $400M | Post-IPO Debt | Nov 05, 2024 |  |
| Mike's Hot Honey | Mike’s Hot Honey is a food and beverage company that offers a chili, pepper-infused honey. The spicy Hot Honey is a delicious pairing with a wide variety of foods including pizza, chicken, ribs, biscuits, salads, fruits, cheeses, and even ice cream. The company was founded in 2010 and headquartered in Brooklyn, New York. | $4.9M | Series B | Jul 01, 2020 |  |
| OrthoAccel Technologies | OrthoAccel Technologies (OATI) designs, develops, markets, and sells the most revolutionary device in orthodontics – the Celerect 1000 – that cuts treatment time for braces in half and works in combination with all existing orthodontic bracket technologies. This proprietary technology (three issued patents) is licensed from the University ofIllinois at Chicago and the company has engaged the leading researchers in this field including the inventor, Dr. Jeremy Mao, at Columbia University, Baylor College of Dentistry, and the University of Texas Health Sciences Center, Dental Branch. Together with these world-class partners, management will commercialize this innovation by 2009. | $15M | Series C | Jan 12, 2017 |  |
| Torax Medical | Torax Medical, Inc., a clinical stage medical device company, develops an implantable device for the treatment of gastroesophageal reflux disease. It provides treatments for digestive diseases, including acid reflux. The company was founded in 2002 and is based in Shoreview, Minnesota. | $25M | Series E | Jul 26, 2016 |  |
| Lattice Engines | Lattice Engines is a computer software company that specializes in the fields of marketing, sales, data-driven business applications, and trigger events. Its applications combine buying signals and apply advanced machine learning to help drive predictable marketing and sales performance.The company was founded in 2006 and is headquartered in SanMateo, California. | $28M | Series D | Jun 10, 2015 |  |
| SportsEngine | SportsEngine is the leading provider of web software and mobile applications for youth, amateur and professional sports. Powering more than 500,000 sports teams, leagues, clubs, and associations, SportsEngine features a complete suite of easy-to-use tools that help sports organizations manage, connect, and communicate with a diverse range ofstakeholders including athletes, parents, administrators, coaches, referees, scouts, volunteers, fans, journalists, and sponsors. | $25M | Series D | Jun 25, 2014 |  |

10 of 35 investments shown.

## Co-investors
- U.S. Bancorp — VC Fund, 4 deals together
- [Boston Millennia Partners](https://shizune.co/investors/profile/boston-millennia-partners) — VC Fund, 3 deals together
- [Dain Rauscher Wessels](https://shizune.co/investors/profile/dain-rauscher-wessels) — VC Fund, 3 deals together
- Kestrel Venture Management — VC Fund, 3 deals together
- [Rho Ventures](https://shizune.co/investors/profile/rho-ventures) — VC Fund, 3 deals together
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Piper Sandler invest in?

Piper Sandler invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series D and Series B stage. Most of the 35 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Piper Sandler?

Public channels for Piper Sandler include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Piper Sandler?

The team at Piper Sandler includes Chad Abraham (Chief Executive Officer), Timothy Carter (Managing Director, Chief Financial Officer) and Tom Schnettler (Vice Chairman , Managing Director), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co